MD
Assistant Professor, Hematology
Clinical Director of Cellular Therapy Program
Medical Director, Adult CAR-T
UNC-Chapel Hill
Clinical Research
Meet Natalie Grover
Area of Interest
My primary research interest is in novel therapies for the treatment of lymphoma. My particular focus is in cellular therapy including innovative approaches to chimeric antigen receptor T-cell (CAR-T) therapy, improving the efficacy of CAR-T cells, and management and prevention of unique toxicities associated with this treatment. My ultimate goal is to improve therapeutic options of lymphoma patients, while minimizing toxicities and maintaining their quality of life.
Awards and Honors
- Oncology K12 Grant, 2018
- ASCO/AACR Methods in Clinical Cancer Research Workshop, 2017
- Cancer Outcomes Research Program Travel Award, UNC Lineberger Comprehensive Cancer Center, 2015
- Department of Medicine Research Grant, University of Virginia, 2012
- Crile Research Fellowship, Case Western Reserve University, 2008
News and Stories
Questions and answers about CAR-T therapy
CAR-T immunotherapy uses your body’s own immune system to help fight cancer. Jonathan Serody, MD, and Natalie Grover, MD, answer some common questions people have about this treatment.
Scientific retreat underscores impact and promise of cancer center’s research
UNC Lineberger's annual scientific retreat brought together faculty, staff and trainees to learn about the latest research at the cancer center.
Engineered safety switch curbs severe side effects of CAR-T immunotherapy
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
Study shows promise for fighting relapsed blood cancer with CAR-T immunotherapy, chemotherapy
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger's Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.
